Avery Dennison has unveiled the AD Minidose U9XM, a new UHF RFID inlay designed for the identification of small pharmaceutical and healthcare items, including syringes, vials, and various packaging formats.
The AD Minidose U9XM is one of the smallest available inlays and is approved for healthcare applications by Auburn University’s RFID Lab. It complies with ARC Category S, making it suitable for source tagging, end-to-end traceability, and product authentication in the healthcare sector.
The inlay’s higher memory capacity allows for the storage of additional product information, such as expiry dates and batch numbers, directly on the item. This ensures reliable access to critical data at any point in the supply chain, reducing dependence on cloud lookups. The ability to store and access this information aids in verifying product authenticity and mitigating the risk of counterfeit goods, contributing to enhanced patient safety and care quality.
Equipped with the NXP U9XM chip, the inlay features a self-adjust function that enhances performance and read reliability, even when items are densely packed in close proximity. The AD Minidose U9XM is available in various memory sizes, ranging from 96 to 496 bits of EPC memory, providing flexibility in encoding, read speed, security, and interoperability.
Mathieu De Backer, Vice President of Innovation & Sustainability at Avery Dennison Smartrac, noted, “We continue to see a growing demand for small, subtle inlays and tags with high memory, particularly for pharmaceutical and healthcare applications. Combining this provision with long-range readability makes the AD Minidose U9XM ideally suited to environments where product authentication and traceability are essential.”